Reporting and Performance of Hepatocellular Carcinoma Risk Prediction Models: Based on TRIPOD Statement and Meta-Analysis

Table 4

The results of metaregression.

Model	Variable		Coefficient	95% CI^‡	t
CU-HCC	Cirrhosis	−0.329	−2.145, 1.488	−0.78	0.518
	Antiviral therapy	0.003	−0.287, 0.293	0.02	0.983
	Multiple time points	3-year	0.561	−0.398, 1.520	1.25	0.230
		5-year	0.479	−0.447, 1.405	1.11	0.286
GAG-HCC	Cirrhosis	—	—	—	—
	Antiviral therapy	−0.078	−0.688, 0.531	−0.31	0.764
	Multiple time points	3-year	0.307	−0.390, 1.003	1.00	0.345
		5-year	—	—	—	—
PAGE-B	Cirrhosis	—	—	—	—
	Antiviral therapy	—	—	—	—
	Multiple time points	3-year	0.0166	−0.319, 0.353	0.13	0.904
		5-year	—	—	—	—
REACH-B	Cirrhosis	−0.611	−1.109, −0.114	−2.71	0.020
	Antiviral therapy	−0.598	−0.771, −0.424	−7.51	0.000
	Multiple time points	3-year	0.457	−0.372, 1.286	1.15	0.264
		5-year	0.064	−0.780, 0.907	0.16	0.877
mREACH-B	Cirrhosis	−0.529	−1.016, −0.042	−2.79	0.038
	Antiviral therapy	−0.020	−0.586, 0.546	−0.11	0.918
	Multiple time points	3-year	0.211	−0.374, 0.796	0.83	0.431
		5-year	−0.044	−0.663, 0.576	−0.16	0.875

^†CI: confidence interval. The symbol means that the information cannot be extracted.